uploads/2018/02/Faslodex.png

How AZN’s Faslodex, Zoladex, Casodex, and Arimidex Performed in 2017

By

Updated

Faslodex’s revenue trends

In 4Q17, AstraZeneca’s (AZN) Faslodex generated revenues of $238.0 million, which reflected ~7.0% growth on a year-over-year (or YoY) basis and a 1.0% decline on a quarter-over-quarter basis.

In fiscal 2017, Faslodex reported revenues of $941.0 million, which is ~13.0% growth on a YoY basis. In 2017, Faslodex’s revenues represented 5.0% of AstraZeneca’s net revenues.

In 2017, in the emerging markets, Faslodex reported revenues of $115.0 million, which reflected ~20.0% YoY growth. In 2017, Faslodex received approval for label expansion in Russia for use in the first-line setting for therapy of postmenopausal women with hormone receptor-positive metastatic breast cancer. 

In Russia, Faslodex generated revenues of $18.0 million of 2017, which reflected ~29.0% YoY growth. The approval of label expansion of Faslodex in Russia primarily contributed to the drug’s sales growth in the country.

In 2017, in the US and Europe, Faslodex reported revenues of $492.0 million and $256.0 million, respectively, which reflected ~12.0% YoY growth in both regions.

In the breast cancer drugs market, some important drugs include Novartis’ (NVS) Afinitor and Tykerb, Pfizer’s (PFE) Ibrance, and Roche’s (RHHBY) Herceptin.

Article continues below advertisement

Zoladex’s revenue trends

In 4Q17, Zoladex reported revenues of $187.0 million, which is an ~20.0% YoY decline and 1.0% quarter-over-quarter growth. In fiscal 2017, Zoladex reported revenues of $735.0 million, which is an ~10.0% YoY decline.

In emerging markets and Europe, Zoladex generated revenues of $353.0 million and $141.0 million, respectively, in 2017, which represents declines of ~1.0% and ~10.0% YoY.

In March 2017, AstraZeneca entered into an agreement with TerSera, in which AstraZeneca sold the Zoladex commercialization rights to TerSera in the US and Canada markets.

Zoladex (goserelin acetate) is indicated for the treatment of advanced prostate cancer.

Casodex’s revenue trends

In 4Q17, Casodex reported revenues of $54.0 million, which is an ~10.0% YoY decline and 6.0% quarter-over-quarter growth.

In fiscal 2017, Casodex reported revenues of $215.0 million, which is an ~13.0% decline on a YoY basis.

Arimidex’s revenue trends

In 4Q17, Arimidex reported revenues of $57.0 million, which reflected ~6.0% growth on a quarter-over-quarter basis. In 4Q17, Arimidex’s YoY revenues remained flat.

In fiscal 2017, Arimidex reported revenues of $217.0 million, which is an ~6.0% decline on a YoY basis.

Advertisement

More From Market Realist